# Esomeprazole in PPI Failures - IMPROVE

> **NCT00272701** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 450 (estimated)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Other PPI marketed in Sweden

## Key facts

- **NCT ID:** NCT00272701
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2009-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272701, "Esomeprazole in PPI Failures - IMPROVE". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00272701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*